Merck Looks Undervalued
October 27, 2015 at 11:00 AM EDT
The wide-moat pharma firm’s third-quarter results were slightly ahead of our expectations, and we think the market continues to underappreciate the value of the company’s pipeline, writes Morningstar’s Damien Conover.
